Emerging clinical data shows that GLP-1 receptor agonists act directly on the brain, cardiovascular network, and immune system to reduce systemic inflammation—far exceeding their well-known role in weight loss.
getty
About one in eight American adults has taken a GLP-1 medication. Roughly 6% are using one right now, according to KFF survey data. Most start because of type 2 diabetes obesity, or both. And increasingly because a spouse it, an employer added coverage, or a telehealth platform provided access after a short intake. Weight loss is what drives demand for these medications. In trials, semaglutide and tirzepatide have produced average body weight reductions in the range of 15% to 21%.
But the weight loss may now the least interesting thing about this drug class in the scientific community. Over the past two years, GLP-1 receptor agonists have piled up randomized trial wins in organs most had never considered when these drugs were initially approved. As a physician who sees patients who take GLP-1s on a regular basis, doctor-patient conversations around these drugs have shifted substantially.
Here are seven non-weight related findings may surprise you, along with the data that supports them.
1. GLP-1s Protect The Kidneys, Independent Of Weight Loss
The FLOW trial randomized 3,533 adults with type 2 diabetes and chronic kidney disease to weekly semaglutide or placebo. It worked so well it was stopped early. Patients on semaglutide had a 24% lower risk of the primary outcome, a combination of kidney failure, a sustained 50% drop in kidney function, kidney-related or cardiovascular death, and kidney function that declined more slowly over time.
This matters because nephrology as a specialty has had very few genuinely disease-modifying options for diabetic kidney disease. GLP-1s are now part of that conversation, and the benefit doesn’t appear to be explained by weight loss alone.
2. GLP-1s Offer An Entirely New Treatment For Sleep Apnea
In the SURMOUNT-OSA trials, adults with obesity and moderate-to-severe obstructive sleep apnea who received tirzepatide, a GLP-1 and GIP agonist, had substantial reductions in the apnea-hypopnea index, a lower hypoxic burden, lower systolic blood pressure, reduced hsCRP—a measure of systemic inflammation–and better patient-reported sleep outcomes.
Anyone who has tried using CPAP long-term understands why this is a big deal. Adherence is often low, and untreated sleep apnea can worsen hypertension, atrial fibrillation and the daytime sleepiness. This can increase the risk of motor vehicle crashes. This new data presents a therapeutic option for sleep apnea.
3. GLP-1s Improve The Liver Injury Related To Metabolic Dysfunction
Metabolic dysfunction-associated steatohepatitis, or MASH, is the leading cause of liver transplants. In the phase 3 ESSENCE trial, 62.9% of patients on weekly semaglutide achieved resolution of steatohepatitis without worsening of fibrosis at 72 weeks. This is compared with 34.3% on placebo, in patients with biopsy-confirmed MASH and stage 2 or 3 fibrosis.
Biopsy-proven histologic improvement is a clinical important in a field that spent two decades watching candidate drugs fail on the same endpoint.
4. GLP-1s Broadly Reduce The Risk Of Addiction
In a cohort study of 606,434 US veterans with type 2 diabetes published in BMJ in March 2026, starting a GLP-1 receptor agonist rather than an SGLT-2 inhibitor was associated with a 14% lower overall risk of developing a substance use disorder. There were broad reductions in alcohol, cannabis, cocaine, nicotine and opioid use.
Among veterans who already had a substance use disorder, GLP-1 use was also associated with fewer drug-related ER visits, fewer overdoses and lower substance-related mortality.
GLP-1 receptors exist in brain regions that process reward, which is the underlying mechanism behind the addiction-related effect. Ostensibly, GLP-1s don’t just quiet the appetite but also impact broader cravings.
5. GLP-1s May Prevent Clots In Chronically Inflamed Patients
Patients with both obesity and an autoimmune disease carry substantially elevated cardiovascular and risk of blood clots. Patients with these conditions were largely excluded from the pivotal GLP-1 trials. A retrospective study published in the Journal of the American Heart Association matched 13,204 GLP-1 users against 13,204 non-users in this population.
The finding: a 31% lower risk of pulmonary embolism, a 17% lower risk of venous thromboembolism, a 13% lower risk of stroke or transient ischemic attacks and a 21% reduction in ER visits. The reduced clotting in GLP-1 users was unexpected. Venous thrombosis is driven by inflammation and obesity-related increases in the coagulability of the blood. Therefore, an anti-inflammatory effect is a plausible explanation for this finding.
6. GLP-1s May Be Linked To Slower Cancer Progression
At the 2026 ASCO Annual Meeting, investigators presented a propensity-matched analysis of 12,112 patients with stage I to III obesity-related cancers who started either a GLP-1 receptor agonist or a gliptin (another drug for diabetes) after the diagnosis. For lung, breast, colorectal and liver cancer, GLP-1 users were 38% to 50% less likely to progress to stage IV disease. High tumor GLP-1 receptor expression was separately associated with a 33% lower risk of death, and a 45% lower risk in breast cancer. Three other tumor types showed fewer metastatic events but were not significant.
Importantly, this was an observational study, meaning it is a weaker form of evidence and does not carry the same weight as a randomized trial. Therefore, at this point, there is not enough data to recommend starting a GLP-1 to slow a cancer. However, this sort of signal is large enough that we may see future trials in this area.
7. There Is A Signal That GLP-1s May Reduce Risks Of Neurological Disease
The most comprehensive picture comes from a Nature Medicine atlas that mapped GLP-1 use against 175 health outcomes in nearly two million veterans with diabetes. Compared with usual care, GLP-1 use was associated with reduced risk: substance use, psychotic disorders, seizures, neurocognitive disorders including Alzheimer’s disease and dementia, coagulation disorders, cardiometabolic disease and infectious illness.
That is a broad list, that it should be interpreted with care. Observational designs at this scale detect associations, not causes. Dementia in particular has a long history of promising real-world signals that don’t stand up to randomized trials.
While large Phase 3 trials like EVOKE and EVOKE+ recently revealed that semaglutide failed to significantly slow early-stage Alzheimer’s progression, they did show positive impacts on markers of brain inflammation and nerve cell damage.
Newer global studies like PROTECT-Cog are now launching to test whether combining GLP-1 drugs with multidomain lifestyle interventions can successfully reduce cognitive decline.
The Macro-Medical Reframe: A New Era for GLP-1s
A drug class with effects this broad also has potential downsides that are equally broad. The same Nature Medicine atlas that catalogued those benefits also flagged elevated risks of pancreatitis, kidney complications and gastrointestinal problems. I have written separately about the less-discussed effects patients report but clinicians rarely counsel on, from menstrual changes and restored fertility to muscle loss. Those belong in the same conversation as the wins listed above.
Here’s good way for patients to think about these new findings. Those on a GLP-1 for weight or diabetes who also have kidney disease, sleep apnea or fatty liver will likely be getting an added benefit. For people with an autoimmune condition or a history of substance use, emerging data are encouraging but are not yet a reason to start or continue the drug on its own.
Large-scale clinical evidence shows that GLP-1 medications do not increase overall cancer risk and may significantly reduce the occurrence and metastatic spread of obesity-related cancers by correcting metabolic dysfunction and inflammation. Importantly, a cautious warning remains only for individuals with rare, specific genetic risks for thyroid cancer.
Ultimately, GLP-1s are turning out to be metabolic and inflammatory drugs that happen to cause weight loss, rather than weight loss drugs with a long list of coincidental improvements.
For insurers, shifting the perspective to an “all-in-one” therapeutic may offer a reframe on how to think about the cost-effectiveness of these drugs. PBMs and payers view a $1,000 monthly line item as an unsustainable cosmetic expense. With these new data, they may need to reconsider them as as an insurance policy against a $50,000 stroke ICU admission or a $150,000 liver transplant.
Embracing this medical paradigm shift will fundamentally change how these therapies are prescribed, how we monitor long-term patient adherence, and ultimately, which patients society deems worthy of coverage.